Quick Answer
CNBX Pharmaceuticals Inc. reported Operating Income Loss of -$271.7 thousand for the year ending 2025.
- CNBX Pharmaceuticals Inc. showed an increase of +53.4% in Operating Income Loss from 2024 to 2025.
- This data is from CNBX Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on December 1, 2025.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: -$4.7 thousand | Q4 2013: -$14.2 thousand | Q1 2014: -$29.3 thousand | Q2 2014: -$4.8 thousand | Q4 2014: -$83.6 thousand | Q1 2015: -$56.6 thousand | Q2 2015: -$153.8 thousand | Q4 2015: -$52.9 thousand | Q1 2016: -$137.3 thousand | Q2 2016: -$13.8 thousand | Q4 2016: -$102.9 thousand | Q1 2017: -$192.5 thousand | Q2 2017: -$472.9 thousand | Q4 2017: -$537.0 thousand | Q1 2018: -$1.70 million | Q2 2018: -$851.8 thousand | Q4 2018: -$648.3 thousand | Q1 2019: -$896.0 thousand | Q2 2019: -$779.5 thousand | Q4 2019: -$815.9 thousand | Q1 2020: -$866.4 thousand | Q2 2020: -$690.5 thousand | Q4 2020: -$659.7 thousand | Q1 2021: -$667.9 thousand | Q2 2021: -$676.3 thousand | Q4 2021: -$1.11 million | Q1 2022: -$730.3 thousand | Q2 2022: -$635.0 thousand | Q4 2022: -$346.8 thousand | Q1 2023: -$250.0 thousand | Q2 2023: -$173.1 thousand | Q4 2023: -$171.9 thousand | Q1 2024: -$206.4 thousand | Q2 2024: -$152.3 thousand | Q4 2024: -$36.8 thousand | Q1 2025: -$64.7 thousand | Q2 2025: -$40.4 thousand | Q4 2025: -$64.0 thousand.
- Over the full 13 years of available data (2013 to 2025), CNBX Pharmaceuticals Inc.'s Operating Income Loss has declined by 367.5%.
- Historical annual values: Fiscal year 2025: -$271.7 thousand | Fiscal year 2024: -$583.1 thousand | Fiscal year 2023: -$931.4 thousand | Fiscal year 2022: -$2.95 million | Fiscal year 2021: -$2.60 million | Fiscal year 2020: -$3.04 million | Fiscal year 2019: -$3.30 million | Fiscal year 2018: -$3.81 million | Fiscal year 2017: -$1.85 million | Fiscal year 2016: -$280.7 thousand | Fiscal year 2015: -$536.5 thousand | Fiscal year 2014: -$216.1 thousand | Fiscal year 2013: -$58.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: